Bank of America’s Barinthus Biotherapeutics BRNS Stock Holding History

Bank of America’s Portfolio BRNS Stock Details BRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-40	Closed	–	–	8277
2021 Q4	$0	Buy	+40	New	+$505	﹤0.01%	8232

Other funds holding BRNS

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

LIP

Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return

BCM

BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

JHU

Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IIM

Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MGIM

M&G Investment Management London, United Kingdom $28.2B AUM 25.87% 1-Year Est. Return

Bank of America's BRNS Position: Q1 2022 in Review

Bank of America sold out of Barinthus Biotherapeutics (BRNS) in Q1 2022, closing a stake of 40 shares.

Bank of America first reported a position in BRNS in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 12 funds tracked by Wall St. Rank hold BRNS as of Q1 2022.

Bank of America reported no remaining Barinthus Biotherapeutics position as of Q1 2022 after selling out during the quarter.
Bank of America sold 40 Barinthus Biotherapeutics shares in Q1 2022.
Bank of America first reported a position in Barinthus Biotherapeutics in Q4 2021 and held it in 1 quarter.
Bank of America's Barinthus Biotherapeutics position peaked at $0 in Q4 2021.
12 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q1 2022.

Based on Bank of America's 13F filing for Q1 2022, filed 16 May 2022.